Compare Hilton Hotels Corporation Common Stock (HLT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $330.2 (market cap $74.18B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 6.7× Repligen Corporation Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 139 Days and Repligen Corporation Common Stock for 0 Days on average.
| HLT | RGEN | |
|---|---|---|
Market Cap | $74.18B | $11.14B |
Volume | 1,295,545 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $194.57 |
52-Week Low | $256.96 | $102.87 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $87.19B | $11.02B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $328.12, up 0.18% on the day, with strong technical momentum as the stock approaches resistance near $330. The company demonstrates solid fundamental performance with revenue growth from $12.04B in 2025 to projected $12.5B in 2026, consistently beating earnings expectations in recent quarters. Analyst sentiment remains bullish with 57% buy ratings and a $350 consensus price target, supported by institutional accumulation and positive travel industry trends.
HLT presents a compelling investment case with strong earnings momentum and global portfolio expansion, though elevated valuation metrics (P/E 48.4) and rising debt levels warrant caution. The stock's proximity to technical resistance and overbought RSI readings suggest potential near-term consolidation before further upside toward analyst targets. Key risks include macroeconomic sensitivity and competitive pressures in the hospitality sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
